Third Rock Hopes To Revolution-ize Natural Products With Its New Biotech
This article was originally published in The Pink Sheet Daily
The venture firm hopes to create its next success story with the launch of Revolution Medicines, a biotech focused on using its chemical platform to transform natural products into drugs with fewer side effects, but more potent efficacy.
You may also be interested in...
Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.